Oruka Therapeutics Stock (NASDAQ:ORKA)


ForecastOwnershipChart

Previous Close

$64.03

52W Range

$10.77 - $91.00

50D Avg

$63.31

200D Avg

$37.33

Market Cap

$2.56B

Avg Vol (3M)

$1.57M

Beta

-0.30

Div Yield

$19.36

ORKA Company Profile


Oruka Therapeutics, Inc. functions as a biotechnology firm primarily dedicated to creating groundbreaking monoclonal antibody therapies. These treatments are designed to address Psoriasis (PsO) along with various other inflammatory and immunological (I&I) conditions. Its current development portfolio includes ORKA-001 and ORKA-002. The company's main operations are based in Menlo Park, CA.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

28

IPO Date

Aug 08, 1997

Website

ORKA Performance


Peer Comparison


TickerCompany
BBOTBridgeBio Oncology Therapeutics Inc.
URGNUroGen Pharma Ltd.
RAPPRapport Therapeutics, Inc. Common Stock
ANABAnaptysBio, Inc.
OCSOculis Holding AG
NRIXNurix Therapeutics, Inc.
KODKodiak Sciences Inc.
XNCRXencor, Inc.
PHATPhathom Pharmaceuticals, Inc.
MNMDMind Medicine (MindMed) Inc.